Pay in 4 interest-free payments of $7.36 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
A total 10 4 cells were included in the analysis for each experiment
:max_bytes(150000):strip_icc()/Health-GettyImages-2200929852-cbe13f76512c4cd3b51252536927920f.jpg)
Trotter, E.W
Trikafta/Kaftrio (elexacaftor/tezacaftor/ivacaftor) Disease area(s): Respiratory/rare disease Manufacturer(s): Vertex Pharmaceuticals Incorporated 2024 Sales (USD): $10.24 billion Why it sold so well: Trikafta (marketed as Kaftrio outside the US), a combination therapy of elexacaftor, tezacaftor and ivacaftor, was the primary driver of Vertex Pharmaceuticals strong commercial performance in 2024
This is particularly important for GLP-1 peptide impurity characterization , where trace-level impurities must be detected with high sensitivity
US$ 25.71
US$ 22.59
US$ 24.44
US$ 24.33
US$ 29.82
US$ 24.32
US$ 27.53
US$ 25.84
US$ 22.62
US$ 22.15
US$ 29.10
US$ 20.71
